MX2012007676A - Nueva formulacion de anticuerpo. - Google Patents

Nueva formulacion de anticuerpo.

Info

Publication number
MX2012007676A
MX2012007676A MX2012007676A MX2012007676A MX2012007676A MX 2012007676 A MX2012007676 A MX 2012007676A MX 2012007676 A MX2012007676 A MX 2012007676A MX 2012007676 A MX2012007676 A MX 2012007676A MX 2012007676 A MX2012007676 A MX 2012007676A
Authority
MX
Mexico
Prior art keywords
antibody formulation
formulation
egfr
preparation
growth factor
Prior art date
Application number
MX2012007676A
Other languages
English (en)
Inventor
Hanns-Christian Mahler
Michael Adler
Ulla Grauschopf
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2012007676A publication Critical patent/MX2012007676A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators

Abstract

La presente invención se refiere a una formulación farmacéutica de un anticuerpo contra el receptor del factor de crecimiento epidérmico (EGFR), a un procedimiento para la preparación de la misma y a usos de la formulación.
MX2012007676A 2009-12-29 2010-12-23 Nueva formulacion de anticuerpo. MX2012007676A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09180840 2009-12-29
PCT/EP2010/070625 WO2011080209A2 (en) 2009-12-29 2010-12-23 Novel antibody formulation

Publications (1)

Publication Number Publication Date
MX2012007676A true MX2012007676A (es) 2012-08-03

Family

ID=43618150

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012007676A MX2012007676A (es) 2009-12-29 2010-12-23 Nueva formulacion de anticuerpo.

Country Status (16)

Country Link
US (1) US20110158987A1 (es)
EP (1) EP2519262A2 (es)
JP (1) JP2013515754A (es)
KR (1) KR20120110175A (es)
CN (1) CN102686241A (es)
AR (1) AR079746A1 (es)
AU (1) AU2010338305A1 (es)
BR (1) BR112012013148A2 (es)
CA (1) CA2783715A1 (es)
IL (1) IL219592A0 (es)
MX (1) MX2012007676A (es)
RU (1) RU2012131099A (es)
SG (1) SG182304A1 (es)
TW (1) TW201200152A (es)
WO (1) WO2011080209A2 (es)
ZA (1) ZA201204266B (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857625B2 (en) 2017-11-23 2024-01-02 UCB Biopharma SRL Pharmaceutical compositions

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2741740T (lt) * 2011-08-12 2017-08-10 Merial, Inc. Biologinių produktų, ypatingai vakcinų, vakuuminis konservavimas
JP6324381B2 (ja) 2012-07-31 2018-05-16 クラウン バイオサイエンス インコーポレイテッド（タイカン） 抗ｅｇｆｒ薬物による処置のための非小細胞肺癌患者を同定するための組織学的マーカー
KR102238677B1 (ko) 2012-09-07 2021-04-12 코히러스 바이오사이언시즈, 인코포레이티드 아달리무맙의 안정한 수성 제형
AR093297A1 (es) * 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
EP2914289B1 (en) 2012-10-31 2019-05-22 Takeda GmbH Lyophilized formulation comprising gm-csf neutralizing compound
UA117466C2 (uk) * 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
CA2906101A1 (en) * 2013-03-15 2014-09-18 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US10745475B2 (en) 2013-08-30 2020-08-18 Takeda Gmbh Antibodies neutralizing GM-CSF for use in the treatment of rheumatoid arthritis or as analgesics
WO2015134406A1 (en) * 2014-03-03 2015-09-11 La Jolla Biologics, Inc. Stable aqueous recombinant protein formulations
WO2015169742A1 (en) 2014-05-07 2015-11-12 Takeda Gmbh Liquid formulation comprising gm-csf neutralizing compound
CN105651848A (zh) * 2014-11-13 2016-06-08 浙江海正药业股份有限公司 一种含有保护剂的毛细管凝胶电泳检测试剂盒
KR101776879B1 (ko) * 2015-01-19 2017-09-08 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
EA037532B1 (ru) * 2015-05-07 2021-04-08 Новиммун Са Способы и композиции для диагностики и лечения заболеваний у пациентов, имеющих повышенные уровни cxcl9 и других биомаркеров
US11091543B2 (en) 2015-05-07 2021-08-17 Swedish Orphan Biovitrum Ag Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications
AU2016329960A1 (en) * 2015-09-28 2018-04-26 Jiangsu Hengrui Medicine Co., Ltd. Stable anti-PD-1 antibody pharmaceutical preparation and application thereof in medicine
US11229702B1 (en) 2015-10-28 2022-01-25 Coherus Biosciences, Inc. High concentration formulations of adalimumab
AU2016368099C1 (en) * 2015-12-07 2023-10-12 Merck Patent Gmbh Aqueous Pharmaceutical Formulation Comprising anti-PD-L1 Antibody Avelumab
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
WO2017184880A1 (en) 2016-04-20 2017-10-26 Coherus Biosciences, Inc. A method of filling a container with no headspace
IT201600077232A1 (it) * 2016-07-22 2018-01-22 Bio Optica Milano S P A Una preparazione liquida acquosa per la conservazione di un campione istologico
AU2017319318A1 (en) * 2016-08-29 2019-02-21 Tiziana Life Sciences Plc Anti-CD3 antibody formulations
CN107773755B (zh) * 2016-08-31 2021-06-22 上海津曼特生物科技有限公司 抗表皮生长因子受体单克隆抗体的注射液制剂
CA3037440A1 (en) * 2016-09-27 2018-04-05 Fresenius Kabi Deutschland Gmbh Liquid pharmaceutical composition
CN107987161B (zh) * 2016-10-26 2021-04-16 泰州迈博太科药业有限公司 一种抗egfr单克隆抗体制剂
CA3060581A1 (en) 2017-05-02 2018-11-08 Merck Sharp & Dohme Corp. Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
CN110506058A (zh) * 2017-06-02 2019-11-26 豪夫迈·罗氏有限公司 免疫激动剂的施用路径
CA3069073A1 (en) * 2017-07-28 2019-01-31 F. Hoffmann-La Roche Ag Bispecific antibody formulation
KR102208378B1 (ko) * 2017-08-17 2021-01-28 주식회사 녹십자 항-egfr 항체를 포함하는 약학 제제
CN110960490A (zh) * 2018-09-28 2020-04-07 江苏恒瑞医药股份有限公司 一种抗egfr抗体偶联药物组合物及其用途
WO2020097141A1 (en) * 2018-11-07 2020-05-14 Merck Sharp & Dohme Corp. Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof
MA55033A (fr) 2019-02-18 2021-12-29 Lilly Co Eli Formulation d'anticorps thérapeutique
MA56102A (fr) * 2019-06-07 2022-04-13 Argenx Bvba Formulations pharmaceutique d'inhibiteurs de fcrn appropriées pour une administration par voie sous-cutanée
CU20190104A7 (es) * 2019-12-17 2021-08-06 Ct Inmunologia Molecular Formulación estable del anticuerpo nimotuzumab
CN113967195A (zh) * 2020-07-22 2022-01-25 三生国健药业（上海）股份有限公司 抗her2/pd1双特异性抗体冻干制剂及其制备方法
WO2022166918A1 (zh) * 2021-02-05 2022-08-11 百奥泰生物制药股份有限公司 一种抗il-5抗体制剂及其制备方法和应用
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物
WO2023246790A1 (zh) * 2022-06-21 2023-12-28 广东菲鹏制药股份有限公司 一种含抗cd47抗体或其抗原结合片段的制剂及其制备方法和应用

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH11510170A (ja) * 1995-07-27 1999-09-07 ジェネンテック インコーポレーテッド タンパク質の処方
US6267958B1 (en) * 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
US20030104996A1 (en) * 2001-08-30 2003-06-05 Tiansheng Li L-methionine as a stabilizer for NESP/EPO in HSA-free formulations
PT1441589E (pt) * 2001-11-08 2012-08-13 Abbott Biotherapeutics Corp Formulação farmacêutica líquida estável de anticorpos igg
ES2574993T3 (es) 2003-01-22 2016-06-23 Roche Glycart Ag Construcciones de fusión y uso de las mismas para producir anticuerpos con mayor afinidad de unión al receptor de Fc y función efectora
DE10355251A1 (de) * 2003-11-26 2005-06-23 Merck Patent Gmbh Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor
RU2007124933A (ru) * 2005-01-28 2009-03-10 Вайет (Us) Стабилизированные жидкие полипептидные составы
NZ556286A (en) * 2005-02-07 2010-11-26 Glycart Biotechnology Ag Antigen binding molecules that bind EGFR, vectors encoding same, and uses thereof
US7700739B2 (en) * 2005-06-30 2010-04-20 Abbott Laboratories IL-12/p40 binding proteins
UA94060C2 (ru) * 2005-09-07 2011-04-11 Эмджен Фримонт Инк. Моноклональное антитело, которое специфически связывает alk-1
JP5405122B2 (ja) * 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
KR20080104160A (ko) * 2006-03-28 2008-12-01 에프. 호프만-라 로슈 아게 항-ｉｇｆ-１ｒ 인간 단일클론 항체 제형
WO2007147001A2 (en) * 2006-06-14 2007-12-21 Imclone Systems Incorporated Lyophilized formulations of anti-egfr antibodies
AR062223A1 (es) * 2006-08-09 2008-10-22 Glycart Biotechnology Ag Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas
EP2094247B1 (en) * 2006-10-20 2022-06-29 Amgen Inc. Stable polypeptide formulations
MX2009006199A (es) * 2006-12-11 2009-06-22 Hoffmann La Roche Formulacion parenteral de anticuerpos abeta.
JP2010531340A (ja) * 2007-07-10 2010-09-24 エフ．ホフマン−ラ ロシュ アーゲー 新規処方物
KR101247418B1 (ko) * 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
US9345661B2 (en) * 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11857625B2 (en) 2017-11-23 2024-01-02 UCB Biopharma SRL Pharmaceutical compositions

Also Published As

Publication number Publication date
KR20120110175A (ko) 2012-10-09
CN102686241A (zh) 2012-09-19
SG182304A1 (en) 2012-08-30
WO2011080209A3 (en) 2012-03-15
AU2010338305A1 (en) 2012-05-24
TW201200152A (en) 2012-01-01
EP2519262A2 (en) 2012-11-07
WO2011080209A2 (en) 2011-07-07
ZA201204266B (en) 2014-11-26
JP2013515754A (ja) 2013-05-09
IL219592A0 (en) 2012-06-28
RU2012131099A (ru) 2014-02-10
CA2783715A1 (en) 2011-07-07
US20110158987A1 (en) 2011-06-30
BR112012013148A2 (pt) 2017-03-21
AR079746A1 (es) 2012-02-15

Similar Documents

Publication Publication Date Title
MX2012007676A (es) Nueva formulacion de anticuerpo.
TW201129381A (en) Antibodies against human CSF-1R and uses thereof
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
MY162825A (en) Antibodies for epidermal growth factor receptor 3 (her3)
MX356337B (es) Anticuerpos contra csf-1r humano y sus usos.
AU2009301431A8 (en) Bispecific anti-VEGF/anti-ANG-2 antibodies
MX2012007340A (es) Anticuerpos anti/her3 y usos de los mismos.
MY171841A (en) Antibody formulation
PH12014502641B1 (en) Activatable antibodies that bind epidermal growth factor receptor and methods of use thereof
WO2011130615A3 (en) Preparation of lacosamide
IL222657A (en) Epidermal Growth Factor Antibody Antibody Preparation (egfr)
HK1197071A1 (en) Antibodies against epidermal growth factor receptor (egfr) and uses thereof (egfr)
WO2011161226A3 (en) Novel antibody formulation
AU2010233994A8 (en) Bispecific anti-ErbB-3/anti-c-Met antibodies
WO2010031720A3 (en) Novel antibody formulation
TN2011000673A1 (en) Bace inhibitors
SG178886A1 (en) Humanized anti-cdcp1 antibodies
MY162411A (en) Crystalline forms of a macrolide, and uses therefor
WO2010070658A3 (en) Improved process for the preparation of endothelin receptor antagonists
AU2011217848A8 (en) Integrin aVB8 neutralizing antibody
EP2615060A4 (en) SILICON NITRIDE POWDER FOR A SILICONUMIDRIDE FLUORESCENCE MATERIAL, SR3AL3SI13O2N21 FLUORESCENCE MATERIAL AND BETA SIALON FLUORESCENCE MATERIAL MANUFACTURED THEREFROM, AND METHOD FOR PRODUCING THEREOF
GB201303865D0 (en) Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein
IN2013MN00733A (es)
EP2576575A4 (en) PROSTAGLANDIN-BISPHOSPHONATE CONJUGATE COMPOUNDS, THEIR METHODS OF MANUFACTURE AND USES THEREOF
MX349563B (es) Formulacion farmaceutica de fenofibrato nanonizado.

Legal Events

Date Code Title Description
FA Abandonment or withdrawal